PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled
Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide)
therapy along with standard supportive care in patients of acute spinal cord injury.